Close Menu

DNAnexus

UK Biobank hopes cloud-based analytics tools will streamline WGS analysis and open the database to researchers who don't otherwise have access to bioinformatics infrastructure.

Regeneron Pharmaceuticals is among the new investors, as the bioinformatics company continues to scale up its multiomics platform to meet growing demand.

In addition to developing standards for proteomics, metabolomics, and other kinds of data, DNAnexus will develop tools to help reviewers quickly and easily assess analysis pipelines.

The five-year FDA contract will add support for multi-omics data and various cloud-based analytical and statistical apps on the PrecisionFDA NGS platform.

The researchers plan to analyze clinical records and genetic data from whole-exome sequencing for more than 3,000 patients using DNAnexus' Apollo platform.

The genome informatics company will apply the new capital to deploy the DNAnexus Apollo platform for multi-omics data science exploration, analysis, and discovery.

Some partners are implementing their solutions on the Azure cloud while others will accept output from Microsoft's genomics pipeline as input into their solutions.

St. Jude Cloud, powered by DNAnexus and Microsoft, offers free access to thousands of WGS records plus cloud-based visualization and computational tools.

The financing, led by new investor Foresite Capital, will help DNAnexus deploy its genome informatics technology and expand its clinical trials presence.

DNAnexus is running a pilot on its genome informatics platform with Google's newly open-sourced DeepVariant variant calling tool.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.